VIVIMEDLAB Share Price | Vivimed Labs Ltd Stock Analysis & Recommendation

Q: When is the next results date for Vivimed Labs Ltd?

The next results date for Vivimed Labs Ltd is scheduled for 13 February 2026.

Q: Should I buy, sell or hold Vivimed Labs Ltd?

Based on the current situation of Vivimed Labs Ltd, it is advisable to consider a strong sell position. The company has not declared any results in the last six months, which raises significant concerns about its operational transparency and financial health. Additionally, the high Debt to EBITDA ratio of 12.57 times indicates a low ability to service its debt, which is a critical red flag for investors. The Return on Equity (ROE) of just 1.75% suggests that the company is struggling to generate profits relative to shareholders' funds.Recent financial results have also been troubling, with a negative profit after tax of Rs -281.57 crore, reflecting a decline of 34.93%. The debt-equity ratio is alarmingly high at 9.60 times, and the debtors turnover ratio is at its lowest point of 2.44 times, indicating inefficiencies in managing receivables.Given these factors, including the lack of recent financial disclosures and the significant drop in profits over the past year, the stock appears to be trading at a risky valuation. Therefore, it would be prudent to consider selling your shares in Vivimed Labs Ltd at this time.

Q: Why is Vivimed Labs Ltd falling/rising?

As of 07-Feb, Vivimed Labs Ltd's stock price is falling, currently at 7.22, which reflects a decrease of 0.37 or 4.87%. The stock has been underperforming significantly, with a decline of 18.42% over the past week, and it has experienced a staggering drop of 40.96% over the past month. Year-to-date, the stock has fallen by 59.05%, while the benchmark Sensex has only decreased by 1.92% during the same period.The stock has been on a consecutive downward trend for the last five days, accumulating a total decline of 22.28% in that timeframe. Additionally, Vivimed Labs Ltd is trading below its moving averages across various timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish trend. Investor participation has also diminished, as evidenced by a significant drop in delivery volume, which fell by 58.46% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's downward movement. Overall, the combination of poor performance metrics, declining investor interest, and trading below moving averages are key factors driving the stock's price decline.

Upcoming Result: Vivimed Labs. will declare its result soon on 13 Feb 2026

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.73 lacs (-40.86%) Volume

Shareholding (Sep 2025)

FII

1.64%

Held by 5 FIIs

DII

0.12%

Held by 0 DIIs

Promoter

7.77%

When is the next results date for Vivimed Labs Ltd?

03-Feb-2026

The next results date for Vivimed Labs Ltd is 13 February 2026.

View full answer

Should I buy, sell or hold Vivimed Labs Ltd?

06-Feb-2026

Why is Vivimed Labs Ltd falling/rising?

07-Feb-2026

As of 07-Feb, Vivimed Labs Ltd's stock price is at 7.22, reflecting a significant decline of 59.05% year-to-date and 40.96% over the past month. The stock is underperforming with decreasing investor interest and trading below its moving averages, indicating a persistent bearish trend.

View full answer

Which are the latest news on Vivimed Labs.?

08-Feb-2026

Vivimed Labs Ltd Hits Lower Circuit Amid Heavy Selling Pressure
Vivimed Labs Ltd is Rated Strong Sell

Compare Vivimed Labs. with Similar Stocks

Dr Reddy's Labs Guj. Inject(Ker)Torrent Pharma

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Low ability to service debt as the company has a high Debt to EBITDA ratio of 12.57 times
The company has been able to generate a Return on Equity (avg) of 1.75% signifying low profitability per unit of shareholders funds

Negative results in Jun 23

Risky - No result in last 6 months

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Drugs

Market cap

INR 61 Cr (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

9.51

Return on Equity

-833.41%

Price to Book

1.60

Revenue and Profits:

Net Sales:

35 Cr

(Quarterly Results - Jun 2023)

Net Profit:

-16 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

-24.0%

4 Years

-66.02%

5 Years

-55.84%

Latest dividend: 0.4 per share ex-dividend date: Sep-19-2018

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Vivimed Labs Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Vivimed Labs Ltd witnessed a sharp decline on 6 Feb 2026, hitting its lower circuit limit of 4.88% as intense selling pressure gripped the stock. The micro-cap pharmaceutical company’s shares closed at ₹7.21, marking a maximum daily loss and continuing a troubling downtrend amid falling investor participation and unfilled supply.

Read full news article

Vivimed Labs Ltd is Rated Strong Sell

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Vivimed Labs Ltd Plunges to Lower Circuit Amid Heavy Selling Pressure

Vivimed Labs Ltd witnessed a sharp decline on 5 Feb 2026, hitting its lower circuit limit of 5%, closing at ₹7.58. The stock faced intense selling pressure, marking its fourth consecutive day of losses and underperforming both its sector and the broader market indices.

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

06-Feb-2026 | Source : BSE

Resignation of CFO

Updates

03-Feb-2026 | Source : BSE

disclosure under regulation 30

Board Meeting Intimation for 31St December 2025 Results

02-Feb-2026 | Source : BSE

Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve 31st december 2025 results

Corporate Actions

BOARD MEETING

13 Feb 2026

DIVIDEND

Vivimed Labs Ltd has declared 20% dividend, ex-date: 19 Sep 18

SPLITS

Vivimed Labs Ltd has announced 2:10 stock split, ex-date: 06 Apr 16

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-32.46%

EBIT Growth (5y)

-213.27%

EBIT to Interest (avg)

-1.77

Debt to EBITDA (avg)

9.69

Net Debt to Equity (avg)

9.51

Sales to Capital Employed (avg)

0.64

Tax Ratio

0.64%

Dividend Payout Ratio

Pledged Shares

14.80%

Institutional Holding

1.76%

ROCE (avg)

-8.47%

ROE (avg)

1.75%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.52

EV to EBIT

-1.51

EV to EBITDA

-2.43

EV to Capital Employed

1.05

EV to Sales

2.52

PEG Ratio

Dividend Yield

ROCE (Latest)

-71.39%

ROE (Latest)

-833.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Non Institution

Pledged Promoter Holdings

14.799

Mutual Funds

Held by 0 Schemes

FIIs

Held by 5 FIIs (1.64%)

Promoter with highest holding

Bbr Projects Private Limited (11.45%)

Highest Public shareholder

Kitara Piin 1102 (9.37%)

Individual Investors Holdings

65.18%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is -4.54% vs -33.57% in Mar 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is 94.14% vs -1,352.70% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.35",
          "val2": "37.03",
          "chgp": "-4.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.33",
          "val2": "-164.30",
          "chgp": "99.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.66",
          "val2": "8.52",
          "chgp": "25.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.58",
          "val2": "-265.99",
          "chgp": "94.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.93%",
          "val2": "-443.69%",
          "chgp": "442.76%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'22",
        "Sep'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "94.33",
          "val2": "119.63",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.88",
          "val2": "0.31",
          "chgp": "-5,867.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18.17",
          "val2": "18.12",
          "chgp": "0.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.23",
          "val2": "-25.63",
          "chgp": "-72.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18.95%",
          "val2": "0.26%",
          "chgp": "-19.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "150.07",
          "val2": "176.15",
          "chgp": "-14.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.01",
          "val2": "-6.98",
          "chgp": "-229.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "27.39",
          "val2": "29.70",
          "chgp": "-7.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.54",
          "val2": "-49.31",
          "chgp": "-26.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15.33%",
          "val2": "-3.96%",
          "chgp": "-11.37%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is -21.15% vs -72.46% in Mar 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -385.63% vs 13.05% in Mar 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "187.10",
          "val2": "237.29",
          "chgp": "-21.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-187.30",
          "val2": "-8.06",
          "chgp": "-2,223.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "35.90",
          "val2": "39.76",
          "chgp": "-9.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-328.53",
          "val2": "-67.65",
          "chgp": "-385.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-100.11%",
          "val2": "-3.40%",
          "chgp": "-96.71%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Jun'23

Mar'23

Change(%)

Net Sales

35.35

37.03

-4.54%

Operating Profit (PBDIT) excl Other Income

-0.33

-164.30

99.80%

Interest

10.66

8.52

25.12%

Exceptional Items

0.00

Consolidate Net Profit

-15.58

-265.99

94.14%

Operating Profit Margin (Excl OI)

-0.93%

-443.69%

442.76%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2023 is -4.54% vs -33.57% in Mar 2023

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2023 is 94.14% vs -1,352.70% in Mar 2023

All Quarterly Results

Half Yearly Results Snapshot (Consolidated) - Sep'22

Sep'22

Sep'21

Change(%)

Net Sales

94.33

119.63

-21.15%

Operating Profit (PBDIT) excl Other Income

-17.88

0.31

-5,867.74%

Interest

18.17

18.12

0.28%

Exceptional Items

0.00

Consolidate Net Profit

-44.23

-25.63

-72.57%

Operating Profit Margin (Excl OI)

-18.95%

0.26%

-19.21%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2022 is -21.15% vs -78.03% in Sep 2021

Consolidated Net Profit

Growth in half year ended Sep 2022 is -72.57% vs -3,185.90% in Sep 2021

All Half Yearly Results

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

150.07

176.15

-14.81%

Operating Profit (PBDIT) excl Other Income

-23.01

-6.98

-229.66%

Interest

27.39

29.70

-7.78%

Exceptional Items

0.00

Consolidate Net Profit

-62.54

-49.31

-26.83%

Operating Profit Margin (Excl OI)

-15.33%

-3.96%

-11.37%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2022 is -14.81% vs -78.58% in Dec 2021

Consolidated Net Profit

YoY Growth in nine months ended Dec 2022 is -26.83% vs 2.03% in Dec 2021

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'23

Mar'23

Mar'22

Change(%)

Net Sales

187.10

237.29

-21.15%

Operating Profit (PBDIT) excl Other Income

-187.30

-8.06

-2,223.82%

Interest

35.90

39.76

-9.71%

Exceptional Items

0.00

Consolidate Net Profit

-328.53

-67.65

-385.63%

Operating Profit Margin (Excl OI)

-100.11%

-3.40%

-96.71%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2023 is -21.15% vs -72.46% in Mar 2022

Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -385.63% vs 13.05% in Mar 2022

All Annual Results

Company CV

About Vivimed Labs Ltd

Vivimed Labs Ltd

Micro Cap

Pharmaceuticals & Drugs

Vivimed Labs Ltd is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations. The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing. The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

Company Coordinates

Company Details

Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403

Tel: 91-8482-232045

http://www.vivimedlabs.com

yugandhar.kopparthi@vivimeslabs.com

Registrar Details

Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad

Vivimed Labs.

1Day

52 Week

CASH

FII

DII

Promoter

When is the next results date for Vivimed Labs Ltd?

Watch in Real-Time

Should I buy, sell or hold Vivimed Labs Ltd?

Why is Vivimed Labs Ltd falling/rising?

Which are the latest news on Vivimed Labs.?

Compare Vivimed Labs. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Negative results in Jun 23

Risky - No result in last 6 months

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

Vivimed Labs Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Vivimed Labs Ltd is Rated Strong Sell

Vivimed Labs Ltd Plunges to Lower Circuit Amid Heavy Selling Pressure

Announcements

Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

Updates

Board Meeting Intimation for 31St December 2025 Results

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Half Yearly Results Snapshot (Consolidated) - Sep'22

Nine Monthly Results Snapshot (Consolidated) - Dec'22

Annual Results Snapshot (Consolidated) - Mar'23

About Vivimed Labs Ltd

Company Coordinates